The approval has been granted by the USFDA to Glenmark Pharmaceuticals, US, for clobetasol propionate foam, 0.05 percent, a generic version of Olux Foam, 0.05 percent, of Mylan Pharmaceuticals, the company said in a statement.
Glenmark Pharmaceuticals on February 18 said it has received final approval from the US health regulator for its generic version of clobetasol propionate foam, a steroid used to treat inflammation and itching of skin.
The approval has been granted by the the United States Food and Drug Administration (USFDA) to Glenmark Pharmaceuticals, US, for clobetasol propionate foam, 0.05 percent, a generic version of Olux Foam, 0.05 percent, of Mylan Pharmaceuticals, the company said in a statement.
Citing IQVIA sales data, Glenmark said, Olux foam 0.05 percent achieved annual sales of approximately $50.9 million in the 12-month period ended December 2018.
The company said its current portfolio consists of 150 products authorised for distribution in the US and 52 ANDA's pending approval with the USFDA.
Shares of Glenmark Pharma were trading at Rs 569 apiece, down 0.11 percent from their previous close, on BSE.
